Key result
Losartan significantly reduced the relative height of the dicrotic notch (47% vs 55%, p<0.01) and pulse wave velocity (8.7 vs 9.3 m/sec, p<0.05) compared to placebo in mild essential hypertension.
Why the study?
Does losartan improve arterial compliance in patients with mild essential hypertension?
Population
16 patients with mild essential hypertension
Comparison
Losartan for 4 weeks vs Placebo for 4 weeks
Design
RCT, randomized cross-over, double-blind
Follow-up
4 weeks
Authors
Loading...
Losartan improves arterial compliance in mild hypertension; extends evidence that optimal agents should target large artery properties beyond BP reduction.
RCT (n=16)
Double-blind
Cross-over
Does losartan improve arterial compliance in patients with mild essential hypertension?
Absolute Event Rate: 47% vs 55%
p-value: p=<0.01
Losartan improves arterial compliance in patients with mild essential hypertension, an effect that appears independent of its blood pressure-lowering properties.
Tor Ole Klemsdal (1999) conducted an RCT in Mild essential hypertension (n=16). Losartan vs. Placebo was evaluated on Relative height of the dicrotic notch (p=<0.01). Losartan significantly reduced the relative height of the dicrotic notch (47% vs 55%, p<0.01) and pulse wave velocity (8.7 vs 9.3 m/sec, p<0.05) compared to placebo in mild essential hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: